Email this article Pharmacoeconomic-guided choice of systemic chemotherapy in metastatic colorectal cancer patients
- Authors: Fedyanin M.Y.1, Tryakin A.A.1, Rogov V.A.2, Ganicheva L.M.2, Frolov M.Y.2, Tyulyandin S.A.1
-
Affiliations:
- N.N. Blokhin National Medical Research Oncology Center, Ministry of Health of Russia
- Volgograd State Medical University, Ministry of Health of Russia
- Issue: Vol 7, No 2 (2017)
- Pages: 36-42
- Section: REVIEW
- Published: 28.09.2017
- URL: https://onco-surgery.info/jour/article/view/217
- DOI: https://doi.org/10.17650/2220-3478-2017-7-2-36-42
- ID: 217
Cite item
Full Text
Abstract
Addition of monoclonal antibodies to metastatic colorectal cancer therapy increases both the survival and treatment costs. This raises the question of economic efficacy of these agents. This review focuses on trials with pharmacoeconomical analysis of chemotherapy and targeted therapy of colorectal cancer.
About the authors
M. Yu. Fedyanin
N.N. Blokhin National Medical Research Oncology Center, Ministry of Health of Russia
Author for correspondence.
Email: edianinmu@mail.ru
Russian Federation
A. A. Tryakin
N.N. Blokhin National Medical Research Oncology Center, Ministry of Health of Russia
Email: edianinmu@mail.ru
Russian Federation
V. A. Rogov
Volgograd State Medical University, Ministry of Health of Russia
Email: edianinmu@mail.ru
Russian Federation
L. M. Ganicheva
Volgograd State Medical University, Ministry of Health of Russia
Email: edianinmu@mail.ru
Russian Federation
M. Yu. Frolov
Volgograd State Medical University, Ministry of Health of Russia
Email: edianinmu@mail.ru
Russian Federation
S. A. Tyulyandin
N.N. Blokhin National Medical Research Oncology Center, Ministry of Health of Russia
Email: edianinmu@mail.ru
Russian Federation
References
Supplementary files
